Semaglutide and tirzepatide are the two most talked-about weight-loss and diabetes drugs in the world. They work in related but different ways, and one produces noticeably more weight loss in trials. Here is a plain-English comparison of how they differ, what the evidence shows, and how to think about choosing between them.
Short answer: Both are highly effective, once-weekly injectables. Tirzepatide (Mounjaro, Zepbound) acts on two gut-hormone receptors and produced the larger average weight loss in trials (around 20%), while semaglutide (Ozempic, Wegovy) acts on one and has the longer real-world track record (around 15%). Neither is “better” for everyone; tolerance, cost, and access matter as much as the headline numbers.
How they work
Both drugs are incretin mimics: they copy gut hormones the body releases after eating, which increase insulin when blood sugar is high, slow stomach emptying, and signal fullness to the brain. The difference is how many pathways each one hits.
- Semaglutide is a single agonist. It activates just the GLP-1 receptor.
- Tirzepatide is a dual agonist. It activates both the GLP-1 receptor and the GIP receptor, a second incretin pathway. That added GIP activity is thought to be why it tends to produce more weight loss.
Head-to-head comparison
| Feature | SemaglutideOzempic / Wegovy | TirzepatideMounjaro / Zepbound |
|---|---|---|
| Mechanism | GLP-1 agonist | Dual GIP + GLP-1 agonist |
| Avg. weight loss (trials) | ~15% (STEP) | ~20% (SURMOUNT) |
| Dosing | Once weekly | Once weekly |
| Maintenance dose | 2.4 mg (weight), up to 2 mg (diabetes) | 5, 10, or 15 mg |
| Half-life | ~7 days | ~5 days |
| Titration | 0.25 → 2.4 mg over ~4 months | 2.5 → 15 mg, +2.5 mg / 4 weeks |
| Approved | 2017 (diabetes), 2021 (obesity) | 2022 (diabetes), 2023 (obesity) |
What the evidence says
The clearest comparison comes from SURPASS-2, a head-to-head trial in people with type 2 diabetes. It pitted tirzepatide directly against semaglutide 1 mg and found tirzepatide produced greater reductions in both HbA1c and body weight across its dose range.
For weight loss specifically, the two drugs were tested in separate flagship programs rather than head to head: semaglutide in the STEP trials (about 15% average body-weight reduction over 68 weeks) and tirzepatide in the SURMOUNT trials (about 15% to 21% depending on dose, over 72 weeks). Cross-trial comparisons are not perfect, but the pattern consistently favors tirzepatide on the scale.
Side effects
The side-effect profiles are very similar because the mechanisms overlap. The most common issues for both are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which are dose-related and tend to ease over time. Both carry the same boxed warning about thyroid C-cell tumors seen in rodents, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. This is exactly why both are dosed on a slow titration schedule: starting low and stepping up limits the nausea.
How dosing differs
Both start low and increase every four weeks, but the numbers are different. Semaglutide climbs from 0.25 mg to a 2.4 mg maintenance dose; tirzepatide climbs from 2.5 mg to as much as 15 mg. If you are reconstituting a compounded vial, the volume you draw depends entirely on how you mix it. Our reconstitution calculator converts any dose into exact syringe units, and each drug’s full titration schedule is on its profile page: semaglutide and tirzepatide.
Which is right?
There is no universal winner. Tirzepatide has the edge on average weight loss and glycemic control in trials. Semaglutide has a longer real-world safety record, more prescriber familiarity, and in many markets better availability and lower cost. Tolerance is individual: some people do better on one than the other. For anyone considering either, the decision belongs with a qualified clinician who can weigh your health history, goals, insurance, and supply.
The bottom line
Tirzepatide’s dual mechanism gives it a measurable advantage on weight loss in the current evidence, but semaglutide remains a highly effective, well-established option. Both are prescription medicines, and compounded or “research” versions sold outside a pharmacy are unregulated. Read the full evidence, dosing, and safety details on the Semaglutide and Tirzepatide reference pages.
This article is educational and reference-only. It is not medical advice. Semaglutide and tirzepatide are prescription medications; consult a qualified healthcare professional before making any decision about your health.
Leave a Reply